Anti-tumour efficacy of IL-1 and IL-2.
The potential value of RIL-1 and RIL-2 for local immunotherapy of cancer was compared in the experimental model of MC-induced sarcomas growing in syngeneic (B10) mice. Highly purified recombinant human RIL-1 (Hoffmann-La Roche) and RIL-2 (Amersham) were administered s.c. into the area of lymph nodes draining the growing tumour. Within the dose range examined, RIL-2 was capable of inducing inhibition of tumour growth or complete regression of tumours and the cure of the majority of treated mice. In contrast, RIL-1 could neither inhibit tumour growth nor potentiate the tumour-inhibitory effect of RIL-2.
Bubeník
J
J
Institute of Molecular Genetics, Czechoslovak Academy of Sciences, Praha.
Indrová
M
M
Holán
V
V
D000818:Animals; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D051381:Rats; D011994:Recombinant Proteins / Q000627:therapeutic use; D012513:Sarcoma, Experimental / Q000628:therapy*
D007375:Interleukin-1; D007376:Interleukin-2; D011994:Recombinant Proteins